Menu Search
Equities

Alector Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0Z2:DUS

Alector Inc

Actions
  • Price (EUR)1.60
  • Today's Change0.10 / 6.67%
  • Shares traded89.00
  • 1 Year change-5.33%
  • Beta0.6316
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

  • Revenue in USD (TTM)69.05m
  • Net income in USD-107.74m
  • Incorporated2017
  • Employees156.00
  • Location
    Alector Inc131 OYSTER POINT BLVD., SUITE 600SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (415) 231-5660
  • Fax+1 (302) 655-5049
  • Websitehttps://alector.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.